(NASDAQ: LYRA) Lyra Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.74%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.81%.
Lyra Therapeutics's earnings in 2025 is -$79,530,000.On average, 2 Wall Street analysts forecast LYRA's earnings for 2025 to be -$2,670,568, with the lowest LYRA earnings forecast at -$3,392,881, and the highest LYRA earnings forecast at -$1,948,256. On average, 1 Wall Street analyst forecast LYRA's earnings for 2026 to be -$19,972,934, with the lowest LYRA earnings forecast at -$19,972,934, and the highest LYRA earnings forecast at -$19,972,934.
In 2027, LYRA is forecast to generate -$17,560,808 in earnings, with the lowest earnings forecast at -$17,560,808 and the highest earnings forecast at -$17,560,808.